|Day Low/High||36.80 / 37.35|
|52 Wk Low/High||33.60 / 54.23|
The drug maker's shares have fallen 6.2% since Wednesday's market open.
The stock has taken a beating, but users of Afrezza are loyal to the drug.
An appeals court in Indiana upheld Eli Lilly's patent regarding Alimta, a major cancer drug for Lilly, keeping Teva and other generic drug specialists at bay.
The price of EpiPens has surged about 25% annually since 2007.
Health insurance giant Cigna said it will no longer cover Mylan's EpiPen.
Cigna will now encourage patients to use either Impax's or Mylan's generic autoinjector. Impax offers cheaper prices, but can its manufacturing keep up?
Donald Trump continued to rip corporate America at a press conference Wednesday, but what else did you missy?
Wall Street secured gains again by late afternoon Wednesday in unpredictable trading following President-elect Donald Trump's first press conference since July.
If Approved, MYL-1401O Has Potential To Be the First Biosimilar Trastuzumab in the U.S.
Cold-Eeze will become Mylan's largest U.S. over-the-counter brand franchise, and builds upon its $1 billion global OTC business.
Next week the J.P. Morgan Healthcare Conference becomes the hottest spot in biotech and pharma.
The biggest annual event for biotech and pharma investors starts Monday with the kickoff of the J.P. Morgan Healthcare Conference in San Francisco.
The largest investor conference for the health care industry kicks off on Monday in San Francisco.
Here are Thursday's top research calls, including upgrades for Etsy and Western Digital, a downgrade for Macy's and new coverage of Adobe.
Allergan raises the prices on nine drugs, but keeps the increases reasonable.
Stocks closed lower on the final trading day of 2016, but all three indices close the year with gains.
The share prices of Mylan, Sears and Endo International fell dramatically in 2016, and the companies face significant challenges ahead.
If you use TVIX and VXX put in an above-market limit order, or if you trade options buy calls on the VIX.
Stocks moved mostly lower on the final day of trading of 2016, but all three indices are poised to close 2016 with gains.
Stocks were falling below the baseline as 2016 comes to a close.
There may be some diamonds-in-the-rough among pharmaceutical consolidators and hospital chains.